查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
全球非小細胞肺癌市場：按類型、治療類型、藥物類別、通路和地區劃分的評估、機會和預測（2016-2030）
市場調查報告書
商品編碼
1388949

全球非小細胞肺癌市場：按類型、治療類型、藥物類別、通路和地區劃分的評估、機會和預測（2016-2030）

Non-Small Cell Lung Cancer Market Assessment, By Type, By Treatment Type, By Drug Class, By Distribution Channel, By Region, Opportunities and Forecast, 2016-2030F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 201 Pages | 商品交期: 3-5個工作天內

價格

2022 年全球非小細胞肺癌 (NSCLC) 市場規模為 106 億美元，在預測期內（2023-2030 年）複合年增長率為 9.5%，到 2030 年還將繼續增長。預計達到219億美元。 全球非小細胞肺癌市場是一個充滿活力的市場，其特點是治療、診斷的不斷進步以及對該疾病的了解不斷加深。

NSCLC是肺癌的主流，約佔所有肺癌病例的85%。 例如，根據 ACS 發布的 2023 年統計數據，預計 2023 年將診斷出約 238,340 名新肺癌患者。 這個市場是由多種因素複雜的相互作用形成的，包括技術創新、不斷發展的治療策略以及日益增強的個人化醫療意識。 精準醫學的進步正在徹底改變非小細胞肺癌的治療，轉向針對每個患者的特定基因突變和生物標記量身定制的標靶治療和免疫療法。

與傳統化療相比，免疫檢查點抑制劑、EGFR抑制劑和ALK抑制劑等標靶治療藥物的出現改善了治療效果並減少了副作用，顯著改變了治療模式。 此外，這一領域正在不斷發展，不斷進行的研究和開發旨在發現新的治療標靶、創新的聯合療法和用於早期檢測的診斷工具。 生物標記驅動的療法、液體活檢和伴隨診斷在治療選擇中發揮關鍵作用，為患者提供更精確、更有效的干預措施。 市場競爭非常激烈，製藥公司正在大力投資研究和臨床試驗，以推出新療法並擴大產品組合。 然而，挑戰依然存在，包括治療成本上升、獲取機會的差異以及需要進行全面的篩檢計劃以早期診斷非小細胞肺癌。

本報告分析了全球非小細胞肺癌市場，提供了產品概述、市場基本結構、整體市場規模趨勢展望、按細分市場和地區劃分的詳細趨勢以及背景市場信息，調查主要影響因素、主要企業概況、市場佔有率等。

目錄

第 1 章研究方法

第 2 章專案範圍與定義

第 3 章新型冠狀病毒感染（COVID-19）對全球非小細胞肺癌市場的影響

第 4 章執行摘要

第 5 章全球非小細胞肺癌市場未來展望（2016-2030）

  • 市場規模與預測
    • 基於金額
    • 基於數量
  • 依類型
    • 鱗狀細胞癌
    • 大細胞癌
    • 腺癌
    • 其他
  • 依治療類型
    • 化療
    • 標靶治療
    • 免疫治療
  • 依藥物類別
    • 血管新生抑制劑
    • EGFR（表皮生長因子受體）抑制劑
    • 激□抑制劑
    • 微管穩定劑
    • 葉酸抗代謝藥
    • PD-1/PD-L1抑制劑
  • 按分銷管道
    • 醫院藥房
    • 藥局/零售藥局
    • 網路藥局
  • 按地區
    • 北美
    • 歐洲
    • 亞太地區
    • 南美洲
    • 中東/非洲
  • 各公司的市佔率（%，2022 年）

第 6 章全球非小細胞肺癌市場未來展望：按地區（2016-2030）

  • 北美*
    • 市場規模與預測
      • 基於金額
      • 基於數量
    • 依類型
    • 依治療類型
    • 依藥物類別
    • 按分銷管道
    • 美國*
      • 市場規模與預測
      • 依類型
      • 依治療類型
      • 依藥物類別
      • 按分銷管道
    • 加拿大
    • 墨西哥

為涵蓋的所有地區/國家提供每個細分市場的資訊。

  • 歐洲
    • 德國
    • 法國
    • 義大利
    • 英國
    • 俄羅斯
    • 荷蘭
    • 西班牙
    • 土耳其
    • 波蘭
  • 南美洲
    • 巴西
    • 阿根廷
  • 亞太地區
    • 印度
    • 中國
    • 日本
    • 澳大利亞
    • 越南
    • 韓國
    • 印尼
    • 菲律賓
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第 7 章市場地圖（2022 年）

  • 依類型
  • 依治療類型
  • 依藥物類別
  • 按分銷管道
  • 按地區

第 8 章宏觀環境與產業結構

  • 需求與供給分析
  • 進出口分析（數量/價值基礎）
  • 供應/價值鏈分析
  • PESTEL 分析
  • 波特五力分析

第 9 章市場動態

  • 生長促進因素
  • 抑製成長的因素（問題、限制）

第 10 章監理架構與創新

  • 臨床試驗
  • 專利情況
  • 監理機關的核准
  • 創新/新興技術

第 11 章主要公司狀況

  • 前 5 名市場領導者：競爭矩陣
  • 前 5 位市場領導者：市場收入分析（%，2022 年）
  • 併購 (M&A)/合資企業（如果適用）
  • SWOT 分析（針對 5 家進入市場的公司）
  • 專利分析（如果適用）

第 12 章價格分析

第 13 章案例研究

第 14 章主要公司展望

  • Novartis AG
    • 公司概況
    • 管理人員
    • 產品/服務
    • 財務狀況（據報告）
    • 重點市場與地域分佈
    • 近期趨勢
  • F. Hoffmann-La Roche Ltd.
  • Bristol-Myers Squibb Company
  • Pfizer Inc.
  • AstraZeneca
  • Eli Lilly and Company
  • Merck &Co., Inc.
  • Boehringer Ingelheim International GmbH
  • Sanofi
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Bayer AG
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Agennix AG.

上面列出的公司並非按市場份額排序，並且可能會根據研究工作中獲得的資訊進行更改。

第 15 章策略建議

第 16 章關於 Market Xcel，免責聲明

Product Code: MX10655

Global non-small cell lung cancer market size was valued at USD 10.6 billion in 2022, and is expected to reach USD 21.9 billion in 2030, with a CAGR of 9.5% for the forecast period between 2023 and 2030F. The global non-small cell lung cancer market is a dynamic landscape characterized by ongoing advancements in treatment modalities, diagnosis, and a growing understanding of the disease.

NSCLC represents a predominant form of lung cancer, constituting approximately 85% of all lung cancer cases. For instance, according to the 2023 statistics published by ACS, about 238,340 new cases of lung cancer are expected to be diagnosed in 2023. This market is shaped by a complex interplay of factors, including technological innovations, evolving therapeutic strategies, and increasing awareness of personalized medicine. Advancements in precision medicine have revolutionized NSCLC treatment, with a shift towards targeted therapies and immunotherapies tailored to specific genetic mutations or biomarkers present in individual patients.

The emergence of immune checkpoint inhibitors and targeted therapies, such as EGFR and ALK inhibitors, has significantly transformed the treatment paradigm, offering improved outcomes and reduced side effects compared to traditional chemotherapy. Moreover, the landscape is continually evolving with ongoing research and development initiatives, aiming to discover novel therapeutic targets, innovative combination therapies, and diagnostic tools for early detection. Biomarker-driven therapies, liquid biopsies, and companion diagnostics play a pivotal role in treatment selection, enabling more precise and effective interventions for patients. Market competition is intense, with pharmaceutical companies investing significantly in research and clinical trials to introduce novel therapies and expand their product portfolios. However, challenges persist, including high treatment costs, access disparities, and the need for more comprehensive screening programs to diagnose NSCLC at earlier stages.

Strategic Partnership Between Key Players

In the dynamic landscape of the global non-small cell lung cancer market, strategic collaborations have emerged as pivotal. Major players, such as pharmaceutical firms and biotech companies, are forging impactful partnerships. Recent alliances between leading diagnostic technology providers and pharmaceutical giants aim to revolutionize treatment through precision medicine and innovative therapies. These collaborations focus on joint research, development, and commercialization, leveraging collective expertise to introduce novel treatments and diagnostic solutions.

This strategic convergence fosters a synergetic approach, propelling advancements in personalized medicine, improving patient outcomes, and reshaping the paradigm of non-small cell lung cancer management globally. For instance, Bristol Myers Squibb, finalized the acquisition of Turning Point Therapeutics on March 6, 2022. Turning Point Therapeutics is a clinical-stage precision oncology company with a lineup of internally developed investigative medications aimed at overcoming major constraints of current cancer treatments. This acquisition expanded Bristol Myers Squibb's oncology portfolio by incorporating late-stage precision oncology asset.

Technological Advancements

The global non-small cell lung cancer market has seen significant technological advancements, revolutionizing treatment approaches. Targeted therapies, such as immunotherapies and precision medicine, have reshaped the landscape. Immunotherapies like checkpoint inhibitors (PD-1/PD-L1 inhibitors) have shown remarkable efficacy in managing advanced NSCLC by enhancing the body's immune response against cancer cells. Additionally, the emergence of personalized medicine, utilizing genetic testing to identify specific mutations or biomarkers, has led to the development of drugs tailored to individual patients.

Liquid biopsies, a minimally invasive diagnostic technique, is gaining prominence for monitoring treatment response and detecting mutations. Furthermore, advancements in imaging technologies like PET scans and MRI have improved early detection and monitoring of NSCLC. In January 2023, Novocure announced the LUNAR study, which assessed the safety and effectiveness of Tumor Treating Fields (TTFields) in combination with standard treatments for stage 4 non-small cell lung cancer (NSCLC) after progression following or during platinum-based therapy, successfully achieved its main objective.

New Innovations

The non-small cell lung cancer market has witnessed groundbreaking innovations aimed at revolutionizing treatment. Immunotherapies like checkpoint inhibitors, such as Pembrolizumab and Nivolumab, have reshaped the landscape by targeting specific proteins to enhance the immune response against cancer cells. Furthermore, targeted therapies like Osimertinib have shown efficacy in specific genetic mutations like EGFR, improving outcomes for patients. Liquid biopsy techniques are emerging, offering less invasive methods to detect genetic mutations, aiding in treatment decisions.

Advancements in precision medicine and biomarker testing are fostering personalized treatment approaches, optimizing therapies for individual patients. Additionally, advancements in combination therapies and innovative drug delivery systems are showing promising results in enhancing treatment efficacy and reducing side effects. During December 2022, the FDA in the United States, provided accelerated approval to Mirati's Krazati (adagrasib), offering a targeted treatment for adult patients diagnosed with KRAS-mutated locally advanced or metastatic non-small cell lung cancer.

Increasing Investment by Companies in Developing Effective Therapies

The global non-small cell lung cancer market is witnessing a significant uptick in investment by companies aimed at developing more effective therapies. This surge in investment underscores a commitment to advancing the field of oncology and addressing the unmet medical needs of patients. Companies are allocating resources to research and develop innovative treatments that encompass targeted therapies, immunotherapies, and precision medicine approaches. The increased focus is driven by a growing understanding of the molecular complexities of non-small cell lung cancer, leading to the identification of new drug targets and treatment strategies.

For example, during January 2023, DeuterOncology, a clinical-stage pharmaceutical firm, concluded a Series A financing round, securing approx. USD 6.1 million (EUR 5.65 million). This investment empowers the company to commence the phase I clinical investigation for its primary product DO-2, an enhanced MET kinase inhibitor designed as a promising targeted therapy for lung cancer, striving to be a top-tier treatment option. Recently, MET inhibitors have gained approval for treating patients with Non-Small Cell Lung Cancer (NSCLC) exhibiting the MET exon 14 skipping mutation.

Impact of COVID-19

The growth of the non-small cell lung cancer market has been significantly impacted by COVID-19. Specifically, the pandemic led to the cessation of over 200 interventional studies, as indicated by clinicaltrials.gov until July 2021, resulting in a deceleration of market expansion. Nevertheless, with the easing of restrictions and the resumption of services, there has been a renewed emphasis on conducting clinical trials for non-small cell lung cancer treatment. Notably, in October 2022, Daiichi Sankyo, Inc., in collaboration with AstraZeneca, initiated a Phase II clinical trial to assess the safety and effectiveness of trastuzumab deruxtecan in treating HER2-mutated metastatic non-small cell lung cancer (NSCLC). These endeavors are anticipated to propel market growth throughout the projected period.

Key Players Landscape and Outlook

The non-small cell lung cancer market is characterized by fragmentation and competitiveness, featuring numerous major players. These companies are implementing diverse strategic approaches like collaborations, partnerships, new product introductions, and other initiatives to maintain their standing in the market. The market features a competitive landscape with several key players driving innovation and therapeutic advancements. Immunotherapies and targeted therapies remain a focus, with ongoing clinical trials and the development of combination therapies. The market outlook is promising, with an increasing emphasis on early detection methods, liquid biopsy technologies, and the exploration of innovative drug delivery systems. Collaboration between key players, academic institutions, and biotech firms continues to drive the evolution of treatment options, underscoring a future of diversified, more effective, and personalized therapies for NSCLC patients.

In June 2022, the European Commission granted approval to Novartis's Tabrecta (capmatinib) as a standalone treatment for adults dealing with advanced non-small cell lung cancer, necessitating systemic therapy after prior treatment with immunotherapy and/or platinum-based chemotherapy.

Table of Contents

1. Research Methodology

2. Project Scope & Definitions

3. Impact of COVID-19 on the Global Non-Small Cell Lung Cancer Market

4. Executive Summary

5. Global Non-Small Cell Lung Cancer Market Outlook, 2016-2030F

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
    • 5.1.2. By Volume
  • 5.2. By Type
    • 1.1.1. Squamous Cell Carcinoma
    • 1.1.2. Large Cell Carcinoma
    • 1.1.3. Adenocarcinoma
    • 1.1.4. Others
  • 5.3. By Treatment Type
    • 1.1.5. Chemotherapy
    • 1.1.6. Targeted Therapy
    • 1.1.7. Immunotherapy
  • 5.4. By Drug Class
    • 1.1.8. Angiogenesis Inhibitor
    • 1.1.9. Epidermal Growth Factor Receptor Blocker
    • 1.1.10. Kinase Inhibitor
    • 1.1.11. Microtubule Stabilizer
    • 1.1.12. Folate Antimetabolites
    • 1.1.13. PD-1/PD-L1 Inhibitor
  • 5.5. By Distribution Channel
    • 1.1.14. Hospital Pharmacy
    • 1.1.15. Drug Store & Retail Pharmacy
    • 1.1.16. Online Pharmacy
  • 5.6. By Region
    • 5.6.1. North America
    • 5.6.2. Europe
    • 5.6.3. Asia-Pacific
    • 5.6.4. South America
    • 5.6.5. Middle East & Africa
  • 5.7. By Company Market Share (%), 2022

6. Global Non-Small Cell Lung Cancer Market Outlook, By Region, 2016-2030F

  • 6.1. North America*
    • 6.1.1. Market Size & Forecast
      • 6.1.1.1. By Value
      • 6.1.1.2. By Volume
    • 6.1.2. By Type
      • 6.1.2.1. Squamous Cell Carcinoma
      • 6.1.2.2. Large Cell Carcinoma
      • 6.1.2.3. Adenocarcinoma
      • 6.1.2.4. Others
    • 6.1.3. By Treatment Type
      • 6.1.3.1. Chemotherapy
      • 6.1.3.2. Targeted Therapy
      • 6.1.3.3. Immunotherapy
    • 6.1.4. By Drug Class
      • 6.1.4.1. Angiogenesis Inhibitor
      • 6.1.4.2. Epidermal Growth Factor Receptor Blocker
      • 6.1.4.3. Kinase Inhibitor
      • 6.1.4.4. Microtubule Stabilizer
      • 6.1.4.5. Folate Antimetabolites
      • 6.1.4.6. PD-1/PD-L1 Inhibitor
    • 6.1.5. By Distribution Channel
      • 6.1.5.1. Hospital Pharmacy
      • 6.1.5.2. Drug Store & Retail Pharmacy
      • 6.1.5.3. Online Pharmacy
    • 6.1.6. United States*
      • 6.1.6.1. Market Size & Forecast
      • 6.1.6.1.1. By Value
      • 6.1.6.1.2. By Volume
      • 6.1.6.2. By Type
      • 6.1.6.2.1. Squamous Cell Carcinoma
      • 6.1.6.2.2. Large Cell Carcinoma
      • 6.1.6.2.3. Adenocarcinoma
      • 6.1.6.2.4. Others
      • 6.1.6.3. By Treatment Type
      • 6.1.6.3.1. Chemotherapy
      • 6.1.6.3.2. Targeted Therapy
      • 6.1.6.3.3. Immunotherapy
      • 6.1.6.4. By Drug Class
      • 6.1.6.4.1. Angiogenesis Inhibitor
      • 6.1.6.4.2. Epidermal Growth Factor Receptor Blocker
      • 6.1.6.4.3. Kinase Inhibitor
      • 6.1.6.4.4. Microtubule Stabilizer
      • 6.1.6.4.5. Folate Antimetabolites
      • 6.1.6.4.6. PD-1/PD-L1 Inhibitor
      • 6.1.6.5. By Distribution Channel
      • 6.1.6.5.1. Hospital Pharmacy
      • 6.1.6.5.2. Drug Store & Retail Pharmacy
      • 6.1.6.5.3. Online Pharmacy
    • 6.1.7. Canada
    • 6.1.8. Mexico

All segments will be provided for all regions and countries covered:

  • 6.2. Europe
    • 6.2.1. Germany
    • 6.2.2. France
    • 6.2.3. Italy
    • 6.2.4. United Kingdom
    • 6.2.5. Russia
    • 6.2.6. Netherlands
    • 6.2.7. Spain
    • 6.2.8. Turkey
    • 6.2.9. Poland
  • 6.3. South America
    • 6.3.1. Brazil
    • 6.3.2. Argentina
  • 6.4. Asia-Pacific
    • 6.4.1. India
    • 6.4.2. China
    • 6.4.3. Japan
    • 6.4.4. Australia
    • 6.4.5. Vietnam
    • 6.4.6. South Korea
    • 6.4.7. Indonesia
    • 6.4.8. Philippines
  • 6.5. Middle East & Africa
    • 6.5.1. Saudi Arabia
    • 6.5.2. UAE
    • 6.5.3. South Africa

7. Market Mapping, 2022

  • 7.1. By Type
  • 7.2. By Treatment Type
  • 7.3. By Drug Class
  • 7.4. By Distribution Channel
  • 7.5. By Region

8. Macro Environment and Industry Structure

  • 8.1. Supply Demand Analysis
  • 8.2. Import Export Analysis - Volume and Value
  • 8.3. Supply/Value Chain Analysis
  • 8.4. PESTEL Analysis
    • 8.4.1. Political Factors
    • 8.4.2. Economic System
    • 8.4.3. Social Implications
    • 8.4.4. Technological Advancements
    • 8.4.5. Environmental Impacts
    • 8.4.6. Legal Compliances and Regulatory Policies (Statutory Bodies Included)
  • 8.5. Porter's Five Forces Analysis
    • 8.5.1. Supplier Power
    • 8.5.2. Buyer Power
    • 8.5.3. Substitution Threat
    • 8.5.4. Threat from New Entrant
    • 8.5.5. Competitive Rivalry

9. Market Dynamics

  • 9.1. Growth Drivers
  • 9.2. Growth Inhibitors (Challenges, Restraints)

10. Regulatory Framework and Innovation

  • 10.1. Clinical Trials
  • 10.2. Patent Landscape
  • 10.3. Regulatory Approvals
  • 10.4. Innovations/Emerging Technologies

11. Key Players Landscape

  • 11.1. Competition Matrix of Top Five Market Leaders
  • 11.2. Market Revenue Analysis of Top Five Market Leaders (in %, 2022)
  • 11.3. Mergers and Acquisitions/Joint Ventures (If Applicable)
  • 11.4. SWOT Analysis (For Five Market Players)
  • 11.5. Patent Analysis (If Applicable)

12. Pricing Analysis

13. Case Studies

14. Key Players Outlook

  • 14.1. Novartis AG
    • 14.1.1. Company Details
    • 14.1.2. Key Management Personnel
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As reported)
    • 14.1.5. Key Market Focus & Geographical Presence
    • 14.1.6. Recent Developments
  • 14.2. F. Hoffmann-La Roche Ltd.
  • 14.3. Bristol-Myers Squibb Company
  • 14.4. Pfizer Inc.
  • 14.5. AstraZeneca
  • 14.6. Eli Lilly and Company
  • 14.7. Merck & Co., Inc.
  • 14.8. Boehringer Ingelheim International GmbH
  • 14.9. Sanofi
  • 14.10. Astellas Pharma Inc.
  • 14.11. Takeda Pharmaceutical Company Limited
  • 14.12. Bayer AG
  • 14.13. Eli Lilly and Company
  • 14.14. GlaxoSmithKline plc.
  • 14.15. Agennix AG.

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

15. Strategic Recommendations

16. About Us & Disclaimer

List of Tables

  • Table 1. Pricing Analysis of Products from Key Players
  • Table 2. Competition Matrix of Top 5 Market Leaders
  • Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 2. Global Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 3. Global Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 4. Global Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 5. Global Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 6. Global Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 7. Global Non-Small Cell Lung Cancer Market Share, By Region, In USD Billion, 2016-2030F
  • Figure 8. North America Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 9. North America Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 10. North America Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 11. North America Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 12. North America Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 13. North America Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 14. North America Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 15. United States Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 16. United States Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 17. United States Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 18. United States Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 19. United States Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 20. United States Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 21. Canada Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 22. Canada Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 23. Canada Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 24. Canada Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 25. Canada Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 26. Canada Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 27. Mexico Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 28. Mexico Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 29. Mexico Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 30. Mexico Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 31. Mexico Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 32. Mexico Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 33. Europe Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 34. Europe Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 35. Europe Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 36. Europe Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 37. Europe Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 38. Europe Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 39. Europe Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 40. Germany Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 41. Germany Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 42. Germany Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 43. Germany Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 44. Germany Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 45. Germany Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 46. France Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 47. France Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 48. France Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 49. France Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 50. France Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 51. France Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 52. Italy Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 53. Italy Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 54. Italy Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 55. Italy Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 56. Italy Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 57. Italy Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 58. United Kingdom Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 59. United Kingdom Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 60. United Kingdom Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 61. United Kingdom Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 62. United Kingdom Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 63. United Kingdom Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 64. Russia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 65. Russia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 66. Russia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 67. Russia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 68. Russia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 69. Russia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 70. Netherlands Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 71. Netherlands Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 72. Netherlands Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 73. Netherlands Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 74. Netherlands Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 75. Netherlands Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 76. Spain Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 77. Spain Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 78. Spain Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 79. Spain Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 80. Spain Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 81. Spain Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 82. Turkey Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 83. Turkey Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 84. Turkey Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 85. Turkey Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 86. Turkey Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 87. Turkey Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 88. Poland Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 89. Poland Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 90. Poland Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 91. Poland Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 92. Poland Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 93. Poland Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 94. South America Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 95. South America Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 96. South America Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 97. South America Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 98. South America Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 99. South America Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 100. South America Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 101. Brazil Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 102. Brazil Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 103. Brazil Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 104. Brazil Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 105. Brazil Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 106. Brazil Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 107. Argentina Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 108. Argentina Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 109. Argentina Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 110. Argentina Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 111. Argentina Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 112. Argentina Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 113. Asia-Pacific Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 114. Asia-Pacific Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 115. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 116. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 117. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 118. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 119. Asia-Pacific Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 120. India Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 121. India Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 122. India Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 123. India Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 124. India Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 125. India Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 126. China Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 127. China Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 128. China Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 129. China Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 130. China Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 131. China Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 132. Japan Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 133. Japan Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 134. Japan Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 135. Japan Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 136. Japan Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 137. Japan Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 138. Australia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 139. Australia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 140. Australia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 141. Australia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 142. Australia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 143. Australia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 144. Vietnam Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 145. Vietnam Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 146. Vietnam Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 147. Vietnam Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 148. Vietnam Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 149. Vietnam Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 150. South Korea Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 151. South Korea Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 152. South Korea Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 153. South Korea Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 154. South Korea Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 155. South Korea Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 156. Indonesia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 157. Indonesia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 158. Indonesia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 159. Indonesia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 160. Indonesia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 161. Indonesia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 162. Philippines Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 163. Philippines Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 164. Philippines Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 165. Philippines Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 166. Philippines Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 167. Philippines Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 168. Middle East & Africa Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 169. Middle East & Africa Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 170. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 171. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 172. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 173. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 174. Middle East & Africa Non-Small Cell Lung Cancer Market Share, By Country, In USD Billion, 2016-2030F
  • Figure 175. Saudi Arabia Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 176. Saudi Arabia Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 177. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 178. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 179. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 180. Saudi Arabia Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 181. UAE Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 182. UAE Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 183. UAE Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 184. UAE Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 185. UAE Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 186. UAE Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 187. South Africa Non-Small Cell Lung Cancer Market, By Value, In USD Billion, 2016-2030F
  • Figure 188. South Africa Non-Small Cell Lung Cancer Market, By Volume, In Thousand Units, 2016-2030F
  • Figure 189. South Africa Non-Small Cell Lung Cancer Market Share, By Type, In USD Billion, 2016-2030F
  • Figure 190. South Africa Non-Small Cell Lung Cancer Market Share, By Treatment Type, In USD Billion, 2016-2030F
  • Figure 191. South Africa Non-Small Cell Lung Cancer Market Share, By Drug Class, In USD Billion, 2016-2030F
  • Figure 192. South Africa Non-Small Cell Lung Cancer Market Share, By Distribution Channel, In USD Billion, 2016-2030F
  • Figure 193. By Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 194. By Treatment Type Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 195. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 196. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2022
  • Figure 197. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2022